Where to buy bosutinib/bosutinib

Bosutinib/Bosutinib is a targeted drug used to treat chronic myelogenous leukemia (CML) (AP, BP Ph+ CML). As a small molecule tyrosine kinase inhibitor, bosutinib is mainly used in patients who are resistant or intolerant to previous treatments. The drug specifically targets Philadelphia chromosome-positive (Ph+) leukemia cells by inhibiting the activity of BCR-ABL tyrosine kinase, thereby preventing cell proliferation and promoting apoptosis. This mechanism allows bosutinib to effectively overcome the resistance problems caused by other tyrosine kinase inhibitors (TKIs) to a certain extent, thus providing patients with new treatment options.

Although bosutinib is widely used internationally, its original drug is not yet on the market in China and therefore cannot currently be included in medical insurance. For patients who need to use bosutinib, they usually need to choose overseas purchasing channels to obtain the drug. In the international market, the original drugs of bosutinib mainly include Turkish version, European version and Swiss version. In addition, some generic drugs of bosutinib are also produced in India. Although the ingredients of these generic drugs are basically the same as those of the original drugs, the specific production processes and quality control may be different.

Patients can obtain bosutinib in a variety of ways. For example, some patients will purchase through international drug purchasing websites. Such websites usually provide drug information from different countries, and patients can choose the appropriate version according to their needs. In addition, there are some companies and individuals who specialize in drug purchasing. They will help patients obtain the drugs they need from overseas pharmacies or hospitals. However, when choosing purchasing channels, patients need to pay special attention to the authenticity of the drugs and related legal risks to ensure that the drugs purchased meet safety standards.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif